Literature DB >> 20813751

The quality of pharmacoeconomic evaluations of age-related macular degeneration therapeutics: a systematic review and quantitative appraisal of the evidence.

William J Foster1, Waqas Tufail, Amalia M Issa.   

Abstract

AIM: To appraise the quality of published pharmacoeconomic studies of therapeutic interventions for age-related macular degeneration (AMD).
METHODS: Systematic review of the literature and evaluation of study quality using the Quality of Health Economic Studies instrument. A systematic search of the English-language literature for economic studies of therapeutic interventions for AMD from 1990 to March 2008 was performed.
RESULTS: A total of 3637 articles were initially identified. Only 24 met eligibility criteria and were rated using the Quality of Health Economic Studies. The mean quality overall rating was 61.6, with quality scores ranging from 18 to 92. There was a higher mean quality score in the studies designed as clinical trials versus observational type designed studies (mean=74.7(11.4), 52.6 (16.5) respectively, p=0.002) and studies in which the statistical analyses were clearly presented versus studies in which the statistical analyses were not so clear (mean=74.3 (12.3), 53.1 (16.1) respectively, p=0.004). Interestingly, government funded studies exhibited a similar mean quality score to studies that were funded by industry (mean=71.0 (15.1), 61.7 (18.5) respectively, p=0.25). A general linear model was fitted using those independent variables which were significantly associated with quality score. The variables 'study design' and 'statistics presented clearly' were found to be jointly significant and explained nearly 70% of the variation in the dependent variable (R(2)=0.68).
CONCLUSIONS: Our analysis reveals that the methodological quality of the health economic analysis of AMD therapeutic interventions in the literature is suboptimal. There is considerable variation in methodological rigour between the articles, and we have identified several attributes that are predictive of study quality.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20813751      PMCID: PMC3108024          DOI: 10.1136/bjo.2009.170282

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  49 in total

Review 1.  The quality of published health economic analyses in digestive diseases: a systematic review and quantitative appraisal.

Authors:  Brennan M R Spiegel; Laura E Targownik; Fasiha Kanwal; Vincent Derosa; Gareth S Dulai; Ian M Gralnek; Chiun-Fang Chiou
Journal:  Gastroenterology       Date:  2004-08       Impact factor: 22.682

Review 2.  Examining the value and quality of health economic analyses: implications of utilizing the QHES.

Authors:  Joshua J Ofman; Sean D Sullivan; Peter J Neumann; Chiun-Fang Chiou; James M Henning; Sally W Wade; Joel W Hay
Journal:  J Manag Care Pharm       Date:  2003 Jan-Feb

3.  Cost of care for patients with age-related macular degeneration in Switzerland and cost-effectiveness of treatment with verteporfin therapy.

Authors:  R A Greiner
Journal:  Semin Ophthalmol       Date:  2001-12       Impact factor: 1.975

4.  Five-year follow-up of fellow eyes of patients with age-related macular degeneration and unilateral extrafoveal choroidal neovascularization. Macular Photocoagulation Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1993-09

5.  Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration.

Authors:  C Hopley; G Salkeld; P Mitchell
Journal:  Br J Ophthalmol       Date:  2004-08       Impact factor: 4.638

6.  Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case.

Authors:  D H Smith; P Fenn; M Drummond
Journal:  Br J Ophthalmol       Date:  2004-09       Impact factor: 4.638

7.  Bilateral macular drusen in age-related macular degeneration. Prognosis and risk factors.

Authors:  F G Holz; T J Wolfensberger; B Piguet; M Gross-Jendroska; J A Wells; D C Minassian; I H Chisholm; A C Bird
Journal:  Ophthalmology       Date:  1994-09       Impact factor: 12.079

8.  Higher risk of multiple falls among elderly women who lose visual acuity.

Authors:  Anne L Coleman; Katie Stone; Susan K Ewing; Michael Nevitt; Steven Cummings; Jane A Cauley; Kristine E Ensrud; Emily L Harris; Marc C Hochberg; Carol M Mangione
Journal:  Ophthalmology       Date:  2004-05       Impact factor: 12.079

Review 9.  CME review: A cost-utility analysis of laser photocoagulation for extrafoveal choroidal neovascularization.

Authors:  Brandon G Busbee; Melissa M Brown; Gary C Brown; Sanjay Sharma
Journal:  Retina       Date:  2003-06       Impact factor: 4.256

10.  Age-related macular degeneration and blindness due to neovascular maculopathy.

Authors:  F L Ferris; S L Fine; L Hyman
Journal:  Arch Ophthalmol       Date:  1984-11
View more
  3 in total

Review 1.  Cost-Effectiveness Models in Age-Related Macular Degeneration: Issues and Challenges.

Authors:  Jordana K Schmier; Carolyn K Hulme-Lowe
Journal:  Pharmacoeconomics       Date:  2016-03       Impact factor: 4.981

2.  Methodological reviews of economic evaluations in health care: what do they target?

Authors:  Maria-Florencia Hutter; Roberto Rodríguez-Ibeas; Fernando Antonanzas
Journal:  Eur J Health Econ       Date:  2013-08-24

Review 3.  A Systematic Review and Critical Appraisal of Economic Evaluations of Pharmacological Interventions for People with Bipolar Disorder.

Authors:  Ifigeneia Mavranezouli; Joran Lokkerbol
Journal:  Pharmacoeconomics       Date:  2017-03       Impact factor: 4.981

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.